TargetReceptor-type tyrosine-protein phosphatase C(Homo sapiens (Human))
Astrazeneca Pharmaceuticals
Curated by ChEMBL
Astrazeneca Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 400nMAssay Description:In vitro inhibitory activity against the cytosolic portion of CD45 protein-tyrosine phosphatase using pNPP as the substrateMore data for this Ligand-Target Pair
TargetTyrosine-protein phosphatase non-receptor type 13(Homo sapiens (Human))
Astrazeneca Pharmaceuticals
Curated by ChEMBL
Astrazeneca Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 4.40E+3nMAssay Description:Inhibitory concentration against FAP-1 pNPPMore data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein phosphatase C(Homo sapiens (Human))
Astrazeneca Pharmaceuticals
Curated by ChEMBL
Astrazeneca Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 4.70E+3nMAssay Description:Inhibitory concentration against CD45 protein-tyrosine phosphatase using lck-10mer as substrateMore data for this Ligand-Target Pair
Affinity DataIC50: >1.00E+4nMAssay Description:Inhibitory concentration against Cathepsin BMore data for this Ligand-Target Pair
TargetTyrosine-protein phosphatase non-receptor type 13(Homo sapiens (Human))
Astrazeneca Pharmaceuticals
Curated by ChEMBL
Astrazeneca Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: >3.00E+4nMAssay Description:Inhibitory concentration against FAP-1 using lck-10 mer as substrateMore data for this Ligand-Target Pair